11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026

May combine two claims.

Both SGLT2 inhibitors and finerenone have shown that the majority of their beneficial effect is mediated by reduction in albuminuria.

“Reduction in albuminuria is also important to evaluate the efficacy of medications prescribed for kidney protection, as both SGLT2 inhibitors and finerenone have shown that the majority of their beneficial effect is mediated by reduction in albuminuria (42,43).”

• cites [42] Agarwal, 2023, Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis, Ann Intern Med sourceNot checked — no full text of the source
• cites [43] Li, 2020, Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes, Kidney Int sourceDisputed

  The ‘Mediating effects in patient subgroups’ section reports that albuminuria (UACR) mediated an estimated 7.4% or 42.3% of canagliflozin’s kidney benefit, depending on baseline UACR—not a majority in either subgroup. The paper studies canagliflozin, not finerenone; the finerenone portion may be covered by the sentence’s other citation. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Compared with placebo, canagliflozin reduced the risk of progression of albuminuria by 27% and the risk of reduction in eGFR, kidney failure, or death from kidney failure by 40%.

“canagliflozin reduced the risk of progression of albuminuria by 27% and the risk of reduction in eGFR, kidney failure, or death from kidney failure by 40%”

• cites [99] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med sourcePartly supported

  The Renal Outcomes section reports hazard ratios of 0.73 for albuminuria progression and 0.60 for the composite renal outcome, corresponding to the cited 27% and 40% relative risk reductions. But the composite specifically required a sustained 40% reduction in eGFR, renal-replacement therapy, or death from renal causes—not any reduction in eGFR or kidney failure generally. The Results section also calls these possible benefits because the prespecified testing sequence did not establish statistical significance. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [104] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med sourceDisputed

  The Methods (Procedures; page unavailable) state that participants were assigned to liraglutide or placebo, not canagliflozin. The Results (Microvascular Outcomes; page unavailable) report a nephropathy hazard ratio of 0.78 for liraglutide; they do not report the claimed 27% and 40% reductions for canagliflozin. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [107] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med sourceDisputed

  The Results and A Primary Outcome sections describe a semaglutide-versus-placebo trial, not a canagliflozin trial. They report a hazard ratio of 0.64 for new or worsening nephropathy, rather than the claimed 27% and 40% risk reductions for canagliflozin. Page numbers are not available in our copy. (LLM, conf=0.87)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Compared with placebo, empagliflozin reduced the risk of incident or worsening nephropathy by 39% and the risk of doubling of serum creatinine accompanied by eGFR ≤45 mL/min/1.73m2 by 44%.

“empagliflozin reduced the risk of incident or worsening nephropathy (a composite of progression to UACR >300 mg/g creatinine, doubling of serum creatinine, kidney failure, or death from kidney failure) by 39% and the risk of doubling of serum creatinine accompanied by eGFR ≤45 mL/ min/1.73m 2 by 44%”

• cites [99] Neal, 2017, Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med sourceDisputed

  The Renal Outcomes section (page not provided) reports results for canagliflozin, not empagliflozin. It reports a hazard ratio of 0.73 for progression of albuminuria and 0.60 for a different composite renal outcome; it does not report the claimed 39% and 44% reductions for the specified outcomes. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [104] Marso, 2016, Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med sourceCould not verify

  The Results (Microvascular Outcomes; page unavailable) report renal outcomes for liraglutide, not empagliflozin. The Discussion mentions empagliflozin only in a comparison of cardiovascular outcomes; a search for its nephropathy and creatinine results found neither the claimed 39% nor 44% reduction in our copy. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [107] Marso, 2016, Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med sourceDisputed

  The Results (A Primary Outcome; page unavailable) report new or worsening nephropathy for semaglutide versus placebo, with a hazard ratio of 0.64—approximately a 36% reduction, not the claimed 39% reduction for empagliflozin. The Other Outcomes table defines doubling of serum creatinine as part of the composite outcome but does not report the claimed 44% reduction for it. (LLM, conf=0.91)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

In a population-based cohort study, addition of a GLP-1 RA on top of SGLT2 inhibitor treatment was associated with a 30% lower risk of major adverse cardiovascular events and 57% lower risk of serious kidney events compared with GLP-1 RA therapy alone after a median follow-up of 9 months.

“The addition of a GLP-1 RA on top of SGLT2 inhibitor treatment was associated with a 30% lower risk of major adverse cardiovascular events and 57% lower risk of serious kidney events compared with GLP-1 RA therapy alone after a median follow-up of 9 months.”

• cites [146] Simms-Williams, 2024, Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study, BMJ sourceDisputed

  Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The incidence of CKD in people with diabetes has decreased over the last decade but remains high in the U.S. and around the world.

“The incidence of CKD in people with diabetes has decreased over the last decade but remains high in the U.S. (3) and around the world (7).”

• cites [3] Tuttle, 2022, Incidence of chronic kidney disease among adults with diabetes, 2015-2020, N Engl J Med sourceSupported
• cites [7] Li, 2021, Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017, J Diabetes Investig sourcePartly supported

  The Results section reports that the global age-standardized incidence rate of CKD due to type 2 diabetes fell from 1990 to 2017, while 2.35 million new cases occurred worldwide in 2017. This supports a substantial continuing global burden, but the paper does not establish a decline specifically over the last decade; it reports that the worldwide number of new cases increased over the full study period. The U.S. portion of the citing sentence is attached to a different citation. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

Measurement of a spot urine sample for albumin alone without simultaneously measuring urine creatinine is less expensive but susceptible to false-negative and false-positive determinations as a result of variation in urine concentration due to hydration.

“Measurement of a spot urine sample for albumin alone (whether by immunoassay or by using a sensitive dipstick test specific for albuminuria) without simultaneously measuring urine creatinine is less expensive but susceptible to falsenegative and false-positive determinations as a result of variation in urine concentration due to hydration (8).”

• cites [8] Yarnoff, 2017, The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease, BMC Nephrol sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

An eGFR persistently <60 mL/min/1.73m2 and/or a urinary albumin value of >30 mg/g creatinine is considered abnormal, though optimal thresholds for clinical diagnosis are debated in older adults over the age of 70 years.

“An eGFR persistently <60 mL/min/1.73m 2 and/or a urinary albumin value of >30 mg/g creatinine is considered abnormal, though optimal thresholds for clinical diagnosis are debated in older adults over the age of 70 years (1,18).”

• cites [1] de Boer, 2022, Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO), Diabetes Care sourcePartly supported

  The Screening and Diagnosis section defines CKD using persistent eGFR <60 mL/min/1.73 m² and/or urine ACR ≥30 mg/g, supporting the threshold claim, although the cited cutoff includes 30 mg/g rather than only values above it. The section does not discuss whether diagnostic thresholds are debated for adults over 70. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [18] Kramer, 2003, Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus, JAMA sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

CKD attributed to diabetes in adults occurs in 20-40% of people with diabetes.

“In this section, the focus is on CKD attributed to diabetes in adults, which occurs in 20-40% of people with diabetes (1)(2)(3)(4).”

• cites [1] de Boer, 2022, Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO), Diabetes Care sourcePartly supported

  The Background reports CKD prevalence above 25% among people with diabetes and estimates that 40% develop CKD during their lifetime. It does not give a 20–40% prevalence range specifically for CKD attributed to diabetes; the 40% figure is a lifetime estimate, not a prevalence estimate. The Screening and Diagnosis section says CKD is usually attributed to diabetes when signs of another cause are absent. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [2] Afkarian, 2016, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014, JAMA sourcePartly supported

  The Clinical Manifestations of DKD section reports that 26.2%–28.4% of US adults with diabetes met the study’s criteria for diabetic kidney disease, within the claimed 20%–40% range. The limitations section says the underlying causes could not be determined and some kidney disease was likely due to causes other than diabetes. Thus the source supports the prevalence range for US adults, but not definitive attribution of every case to diabetes or an unqualified estimate for adults elsewhere. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [3] Tuttle, 2022, Incidence of chronic kidney disease among adults with diabetes, 2015-2020, N Engl J Med sourceCould not verify

  The “To the Editor” section reports CKD incidence among adults with diabetes in two U.S. health care systems, not the proportion of people with diabetes who have CKD. Searches for the 20–40% figure and CKD prevalence found no passage in our copy supporting that estimate; no page number is available. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

The combination of both filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone.

“The combination of both filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone (16,19).”

• cites [16] Inker, 2021, New creatinine- and cystatin C-based equations to estimate GFR without race, N Engl J Med sourceSupported
• cites [19] Fan, 2015, Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals, J Am Soc Nephrol sourceSupported

May combine two claims.

UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes.

“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,11,12).”

• cites [6] Fox, 2012, Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis, Lancet sourceSupported
• cites [11] Afkarian, 2013, Kidney disease and increased mortality risk in type 2 diabetes, J Am Soc Nephrol sourceNot checked — no full text of the source
• cites [12] Groop, 2009, The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes, Diabetes sourcePartly supported

  The Methods (page unavailable) define ranges of urinary albumin excretion, and the Results report different all-cause mortality rates across those ranges in adults with type 1 diabetes. The paper does not show that differences *within* the normal or abnormal ranges predict kidney or cardiovascular outcomes; it examines albuminuria categories and all-cause mortality, not UACR as a continuous predictor of those outcomes. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Reduced eGFR without albuminuria has been frequently reported in type 1 and type 2 diabetes and is becoming more common over time as the prevalence of diabetes increases in the U.S.

“Reduced eGFR without albuminuria has been frequently reported in type 1 and type 2 diabetes and is becoming more common over time as the prevalence of diabetes increases in the U.S. (2,3,18,20,21).”

• cites [2] Afkarian, 2016, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014, JAMA sourcePartly supported

  The introduction says reduced GFR without albuminuria has been frequently described, and the Clinical Manifestations of DKD section reports it in 8.9% of adults with diabetes in one survey period. The Results and Discussion report that reduced eGFR overall became more prevalent among US adults with diabetes, but do not establish a trend specifically for reduced eGFR without albuminuria or separately for type 1 and type 2 diabetes. The Discussion says the reasons for the increase in reduced eGFR cannot be conclusively determined, so it does not support attributing the trend to increasing diabetes prevalence. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [3] Tuttle, 2022, Incidence of chronic kidney disease among adults with diabetes, 2015-2020, N Engl J Med sourcePartly supported

  In “TO THE EDITOR” (page unavailable), the paper treats reduced eGFR as a CKD criterion independent of albuminuria and notes a large increase in diabetes prevalence. It does not report how frequently reduced eGFR occurs without albuminuria in type 1 or type 2 diabetes, or show that this phenotype is becoming more common. Its measured outcome—overall CKD incidence among adults with diabetes—declined from 2015–2016 to 2019–2020. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [18] Kramer, 2003, Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus, JAMA sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

CKD can progress to kidney failure requiring dialysis or kidney transplantation and is the leading cause of kidney failure in the U.S.

“CKD can progress to kidney failure requiring dialysis or kidney transplantation and is the leading cause of kidney failure in the U.S. (5).”

• cites [5] Johansen, 2021, US Renal Data System 2020 Annual Data Report: epidemiology of kidney disease in the United States, Am J Kidney Dis sourcePartly supported

  The report’s ESRD discussion (page not provided) confirms that people with kidney failure receive dialysis or kidney transplants. It does not state that CKD is the leading cause of kidney failure in the U.S., and the passages do not explicitly describe progression from CKD to kidney failure. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

Among people with type 1 or type 2 diabetes, the presence of CKD markedly increases cardiovascular risk and health care costs.

“In addition, among people with type 1 or type 2 diabetes, the presence of CKD markedly increases cardiovascular risk and health care costs (6).”

• cites [6] Fox, 2012, Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis, Lancet sourcePartly supported

  The Introduction and Discussion report increased cardiovascular mortality risk in people with diabetes and CKD. The paper does not report health care costs or separate findings for type 1 and type 2 diabetes; its measured cardiovascular outcome is mortality, not cardiovascular risk more broadly. The supplied passages have no page numbers. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Semiquantitative or qualitative dipstick screening will need to be confirmed by UACR values in an accredited laboratory.

“Thus, semiquantitative or qualitative (dipstick) screening will need to be confirmed by UACR values in an accredited laboratory (9,10).”

• cites [9] Coresh, 2019, Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies, Lancet Diabetes Endocrinol sourceCould not verify

  The Methods (Procedures; page unavailable) describe measuring albuminuria by ACR, and the Discussion (page unavailable) notes the value of repeat albuminuria testing. Neither passage addresses confirming qualitative or semiquantitative dipstick screening with UACR in an accredited laboratory; searches for dipstick screening and confirmation found no such recommendation. (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites [10] Levey, 2020, Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency, Am J Kidney Dis sourceNot checked — no full text of the source

May combine two claims.

At any eGFR, the degree of albuminuria is associated with risk of cardiovascular disease, CKD progression, and mortality.

“At any eGFR, the degree of albuminuria is associated with risk of cardiovascular disease (CVD), CKD progression, and mortality (6).”

• cites [6] Fox, 2012, Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis, Lancet sourcePartly supported

  The Results (page not available in our copy) associate higher albuminuria with greater all-cause and cardiovascular mortality across eGFR–albuminuria categories; they also report increasing ESRD risk with higher albuminuria. The paper examines cardiovascular mortality rather than cardiovascular disease generally, and ESRD rather than CKD progression more broadly, so those parts of the claim exceed its reported outcomes. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have overall reported cardiovascular and kidney outcome benefits.

“Remission of albuminuria may occur spontaneously, and cohort studies evaluating associations of change in albuminuria with clinical outcomes have overall reported cardiovascular and kidney outcome benefits (9,45,46).”

• cites [9] Coresh, 2019, Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies, Lancet Diabetes Endocrinol sourcePartly supported

  The Discussion (page not provided) reports that reduced albuminuria was associated with lower subsequent ESKD risk, and cites earlier observational analyses linking albuminuria change to cardiovascular mortality. It describes variation in albuminuria without intervention, but does not establish that albuminuria can remit spontaneously; that part of the claim is unsupported. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [45] de Boer, 2016, Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC Study, Clin J Am Soc Nephrol sourcePartly supported

  The Discussion reports that remission occurred with and without RAS inhibitor treatment, although the study could not fully determine its cause. It also reports a kidney-risk benefit for regression of macroalbuminuria, but its principal finding is that remission of microalbuminuria was not associated with improved cardiovascular or renal outcomes. Thus this cohort does not support the claim of cardiovascular and kidney outcome benefits across albuminuria remission. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [46] Sumida, 2017, Changes in albuminuria and subsequent risk of incident kidney disease, Clin J Am Soc Nephrol sourceNot checked — no full text of the source

May combine two claims.

Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes and type 2 diabetes.

“Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large, randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes (54,55) and type 2 diabetes (1,56,57).”

• cites [54] DCCT/EDIC Research Group, 2014, Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study, Lancet Diabetes Endocrinol sourcePartly supported

  The Introduction and Results report that intensive treatment aimed at near-normal glycaemia reduced incident microalbuminuria and macroalbuminuria in people with type 1 diabetes. But the Results report fewer cases of impaired eGFR—not a reduction in eGFR itself. The type 2 diabetes portion of the citing sentence has separate citations and is not attributed to this paper. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [55] de Boer, 2011, Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes, N Engl J Med sourcePartly supported

  The Methods (Study Population; page not provided) describe a large randomized trial in type 1 diabetes targeting blood glucose near the nondiabetic range, and the introductory passage under Abstract > Conclusions reports reduced albuminuria risk. Results (Rates of Decrease in GFR; page not provided) show that intensive therapy lowered mean eGFR during the trial but was associated with higher eGFR and a slower decline during long-term follow-up. Thus, an unqualified claim that it ‘reduce[s] eGFR’ does not reflect the full finding. The type 2 diabetes portion has separate citations and is not attributed to this paper. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [1] de Boer, 2022, Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO), Diabetes Care sourcePartly supported

  The Glycemic Control > Individualized Targets section (page unavailable) says RCT-based glycemic targets are associated with fewer microvascular complications and a lower risk of CKD progression in people with diabetes. It does not specifically say that near-normoglycemia delays the onset and progression of albuminuria, and it does not report that intensive glucose lowering reduces eGFR; the discussion of slower eGFR decline concerns GLP-1 receptor agonists. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Observed history of eGFR loss and cause of kidney damage may affect treatment decisions.

“Observed history of eGFR loss (which is also associated with risk of CKD progression and other adverse health outcomes) and cause of kidney damage (including possible causes other than diabetes) may also affect these decisions (25).”

• cites [25] Vassalotti, 2016, Practical approach to detection and management of chronic kidney disease for the primary care clinician, Am J Med sourcePartly supported

  The Abstract says the cause of CKD fundamentally affects management, and section 2.1.4 recommends reviewing management when CKD progresses. The paper also defines progression using eGFR decline. However, its discussion of other adverse outcomes concerns low eGFR, not specifically a history of eGFR loss, so that parenthetical is not fully supported. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Serum potassium should be monitored in individuals treated with diuretics because these medications can cause hypokalemia, which is associated with cardiovascular risk and mortality.

“Serum potassium should also be monitored in individuals treated with diuretics because these medications can cause hypokalemia, which is associated with cardiovascular risk and mortality (38)(39)(40).”

• cites [38] Hughes-Austin, 2017, The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals, Clin J Am Soc Nephrol sourceNot checked — no full text of the source
• cites [39] Bandak, 2017, Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project, J Am Heart Assoc sourceCould not verify

  The Introduction and Discussion (pages unavailable) address potassium monitoring after ACE-inhibitor or ARB initiation and the mortality risk associated with hyperkalemia. Searches for diuretic-induced hypokalemia found no passage linking it to cardiovascular risk or mortality, or recommending monitoring for that reason. The Results instead identify potassium-sparing diuretics as a risk factor for hyperkalemia in ACE-inhibitor or ARB users. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [40] Nilsson, 2017, Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system, Int J Cardiol sourcePartly supported

  The Results (p. 5) identify loop/thiazide diuretics as a strong risk factor for hypokalemia, and the Conclusion (p. 6) calls for better potassium-monitoring strategies. The paper does not establish the claimed association between hypokalemia and cardiovascular risk or mortality; its discussion of increased mortality risk (p. 6) concerns hyperkalemia. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

The National Kidney Foundation Kidney Disease Outcomes Quality Initiative and the International Society of Renal Nutrition and Metabolism recommend a lower protein intake level (0.6-0.8 g/kg/day) for kidney protection and state that this lower level is relatively safe.

“The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) (49) and the International Society of Renal Nutrition and Metabolism (50) recommend a lower protein intake level (0.6-0.8 g/ kg/day) for kidney protection and state that this lower level is relatively safe.”

• cites [49] Ikizler, 2020, KDOQI clinical practice guideline for nutrition in CKD: 2020 update, Am J Kidney Dis sourceNot checked — no full text of the source
• cites [50] Rhee, 2023, Nutritional and dietary management of chronic kidney disease under conservative and preservative kidney care without dialysis, J Ren Nutr sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

In people with CKD and diabetes, consuming protein below the recommended daily allowance of 0.8 g/kg/day does not alter blood glucose levels, cardiovascular risk measures, or the course of GFR decline.

“In people with CKD and diabetes, consuming protein below the recommended daily allowance of 0.8 g/kg/day is not recommended, because it does not alter blood glucose levels, cardiovascular risk measures, or the course of GFR decline (48).”

• cites [48] Klahr, 1994, The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group, N Engl J Med sourcePartly supported

  The Methods (p. 1) compare protein diets below 0.8 g/kg/day, and Study 2 (p. 5) reports no statistically significant difference in average GFR decline between its diet groups. But this was not a finding specific to people with diabetes: only 3% of participants had non-insulin-dependent diabetes (Base-Line Characteristics, p. 2). The paper does not establish the claimed lack of effects on blood glucose or cardiovascular risk measures, and its Discussion (p. 7) describes a possible small benefit for renal progression rather than showing no effect. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Individualization of potassium intake may be necessary to manage serum potassium concentrations.

“Restriction of dietary sodium (to <2,300 mg/day) may be useful to manage blood pressure and reduce cardiovascular risk (51,52), and individualization of potassium intake may be necessary to manage serum potassium concentrations (27,38,39).”

• cites [27] James, 2015, A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury, Am J Kidney Dis sourceCould not verify

  The Methods (Exposure variables and Effect modification variables; pages unavailable) describe kidney-function measures, albuminuria, diabetes, and hypertension, not dietary potassium or serum potassium management. Searches for individualized potassium intake and for dietary potassium, serum potassium, and hyperkalemia found no passage addressing the attributed advice. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [38] Hughes-Austin, 2017, The relation of serum potassium concentration with cardiovascular events and mortality in community-living individuals, Clin J Am Soc Nephrol sourceNot checked — no full text of the source
• cites [39] Bandak, 2017, Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project, J Am Heart Assoc sourceCould not verify

  The Discussion recommends tailoring potassium monitoring to individual patients, not individualizing dietary potassium intake. It mentions lower potassium intake among women only as a possible explanation for a risk difference. Searches for dietary potassium intake and restriction found no passage addressing intake as a way to manage serum potassium concentrations; page numbers were unavailable in our copy. (LLM, conf=0.75)

  Experimental — accuracy not yet measured

May combine two claims.

Early changes in kidney function may be detected by increases in albuminuria before changes in eGFR, and this also significantly affects cardiovascular risk.

“Early changes in kidney function may be detected by increases in albuminuria before changes in eGFR (41), and this also significantly affects cardiovascular risk.”

• cites [41] Zelniker, 2021, Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial, JAMA Cardiol sourcePartly supported

  The Study Population section reports albuminuria in patients whose eGFR was not below 60 mL/min/1.73 m², supporting its use as a marker when eGFR is preserved. The CV Outcomes by Markers of CKD in the Placebo Group section also reports higher cardiovascular event rates among patients with albuminuria alone. But these are baseline categories, not evidence that albuminuria increased before an individual's eGFR changed. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Hattori et al. found that among participants with eGFR 10-60 mL/min/1.73m2 who had ACE inhibitors or ARBs stopped, those who restarted had better long-term kidney outcomes and lower mortality, with no significant difference in hyperkalemia.

“Hattori et al. (91) evaluated 6,065 participants between 2005 and 2021 (∼40% had diabetes) with eGFR ranging from 10 to 60 mL/min/1.73m 2 who had ACE inhibitors or ARBs stopped (usually due to hyperkalemia or AKI) and found that those who restarted the ACE inhibitor or ARB had better long-term kidney outcomes and lower mortality (there was no significant difference in hyperkalemia in those who re”

• cites [91] Hattori, 2024, Estimated effect of restarting renin-angiotensin system inhibitors after discontinuation on kidney outcomes and mortality, J Am Soc Nephrol sourceSupported

May combine two claims.

SGLT2 inhibitors reduce kidney tubular glucose reabsorption, weight, systemic blood pressure, intraglomerular pressure, and albuminuria and slow GFR loss through mechanisms that appear independent of glycemia.

“For example, SGLT2 inhibitors reduce kidney tubular glucose reabsorption, weight, systemic blood pressure, intraglomerular pressure, and albuminuria and slow GFR loss through mechanisms that appear independent of glycemia (31,(97)(98)(99)(100)(101).”

• cites [31] Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med sourcePartly supported

  The introduction (p. 324) says empagliflozin reduces renal glucose reabsorption, weight, blood pressure, and intraglomerular pressure; Renal Outcomes reports less progression to macroalbuminuria, and Renal Function over Time reports slower eGFR decline than with placebo. The Discussion says changes in hyperglycemia and other risk factors are unlikely to fully explain the renal benefit, but does not establish that the mechanisms are independent of glycemia. The evidence is for empagliflozin in the studied populations, rather than SGLT2 inhibitors as a class. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [97] Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation sourcePartly supported

  The Discussion reports reduced tubular glucose reabsorption, body weight, blood pressure, and hyperfiltration after SGLT2 inhibition; it treats reduced intraglomerular pressure as an inferred mechanism. It cites a reduction in proteinuria in patients with type 2 diabetes, but does not establish reduced albuminuria in its own participants. Crucially, the Discussion says long-term renal protection is not yet known, so this paper does not support the claim that SGLT2 inhibitors slow GFR loss; it also does not establish that all the listed effects are independent of glycemia. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [98] Heerspink, 2017, Canagliflozin slows progression of renal function decline independently of glycemic effects, J Am Soc Nephrol sourceNot checked — no full text of the source

May combine two claims.

In a trial of people with type 2 diabetes and normal urinary albumin excretion, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events.

“In a trial of people with type 2 diabetes and normal urinary albumin excretion, an ARB reduced or suppressed the development of albuminuria but increased the rate of cardiovascular events (94).”

• cites [94] Haller, 2011, Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes, N Engl J Med sourcePartly supported

  The Background identifies the trial population as patients with type 2 diabetes and normoalbuminuria, and the Discussion reports that ARB therapy delayed the onset of microalbuminuria by 23%. The Cardiovascular End Points section reports more cardiovascular deaths with olmesartan (15 vs. 3), but the overall cardiovascular composite was similar between groups (4.3% vs. 4.2%). Thus, the claim overstates the finding as an increase in cardiovascular events generally. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

Among individuals with diabetes and/or CKD receiving ACE inhibitor or ARB therapy, SGLT2 inhibitor initiation was associated with a lower risk of hyperkalemia (HR 0.89 [95% CI 0.82-0.96]) and ACE inhibitor or ARB therapy discontinuation compared with nonusers (36% vs. 45%; P < 0.001).

“Among individuals with diabetes and/or CKD receiving an ACE inhibitor or ARB therapy, SGLT2 inhibitor initiation was associated with a lower risk of hyperkalemia (HR 0.89 [95% CI 0.82-0.96])and ACE inhibitor or ARB therapy discontinuation compared with nonusers (36% vs. 45%; P < 0.001) (88).”

• cites [88] Wing, 2025, SGLT2 inhibitors and risk for hyperkalemia among individuals receiving RAAS inhibitors, JAMA Intern Med sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

Two clinical trials studied combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI).

“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (95,96).”

• cites [95] Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med sourcePartly supported

  The Discussion (page unavailable) reports that adding telmisartan to ramipril gave no significant benefit for the primary cardiovascular outcome and increased renal dysfunction and hyperkalemia. This paper is one trial, not both trials cited in the sentence. It does not establish a lack of benefit for CKD specifically, and it reports renal dysfunction rather than explicitly identifying acute kidney injury. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [96] Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med sourceNot checked — no full text of the source

May combine two claims.

While glucose-lowering effects of SGLT2 inhibitors are blunted with eGFR <45 mL/min/1.73m2, kidney and cardiovascular benefits were still seen at eGFR levels as low as 20 mL/min/1.73m2 even with no significant change in glucose.

“while the glucose-lowering effects of SGLT2 inhibitors are blunted with eGFR <45 mL/min/1.73m 2 , the kidney and cardiovascular benefits were still seen at eGFR levels as low as 20 mL/min/ 1.73 m 2 even with no significant change in glucose (4,29,31,107,123,127,129,130).”

• cites [4] 4. DCCT/EDIC Research Group, 2014, Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study, Diabetes Care sourceCould not verify

  The Results > Impaired GFR section reports kidney outcomes after intensive glucose-lowering therapy in DCCT/EDIC, not treatment with SGLT2 inhibitors. Searches for SGLT2 inhibitors and the eGFR thresholds of 45 and 20 found no passage addressing the claimed glucose-lowering, kidney, or cardiovascular effects at those levels. No page numbers were available in our copy. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [29] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med sourcePartly supported

  The Discussion reports kidney and cardiovascular benefits with canagliflozin despite modest differences in blood glucose, including among patients with reduced baseline eGFR. But the Methods enrolled patients with eGFR of 30 to <90 mL/min/1.73 m², and the paper says it excluded those below 30; it cannot establish benefits at 20. The Effect on Intermediate Outcomes section also reports a small but statistically significant difference in glycated hemoglobin, rather than no significant glucose change. Our copy does not establish the claimed blunting threshold of <45. (LLM, conf=0.91)

  Experimental — accuracy not yet measured
• cites [31] Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med sourcePartly supported

  The Results report participants with baseline eGFR of 30–44 mL/min/1.73 m², and the Renal Outcomes section reports kidney benefits with empagliflozin; Figure 2 (p. 330) also reports a benefit for the composite of nephropathy or cardiovascular death. The cited passages do not establish benefits at eGFR as low as 20, blunted glucose lowering below 45, or benefits occurring without a significant change in glucose. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In CREDENCE, there was a 31% reduction in cardiovascular death or heart failure hospitalization and a 20% reduction in cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

“there were clear benefits on cardiovascular outcomes demonstrating a 31% reduction in cardiovascular death or heart failure hospitalization and a 20% reduction in cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (29,125,126).”

• cites [29] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med sourceSupported
• cites [125] Bakris, 2019, Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors, Am J Kidney Dis sourcePartly supported

  The main text says CREDENCE supports reduced cardiovascular risk in people with type 2 diabetes, but it does not report either the 31% reduction in cardiovascular death or heart-failure hospitalization or the 20% reduction in cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Searches for both outcome phrases found no matching figures; the text’s 31% refers instead to the proportion of CREDENCE participants with CKD stages 3b–4. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [126] Mahaffey, 2019, Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups, Circulation sourcePartly supported

  The Results section, “Cardiovascular Outcomes by Primary and Secondary Prevention” (page unavailable), reports reduced major cardiovascular events with canagliflozin, and the Discussion describes cardiovascular benefit in both prevention groups. Our copy does not state the claimed 31% or 20% reductions for the two composites; searches for those percentages and corresponding hazard ratios did not establish them. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

CREDENCE was stopped early due to positive efficacy and showed a 32% risk reduction for development of kidney failure over placebo.

“It was stopped early due to positive efficacy and showed a 32% risk reduction for development of kidney failure over placebo (29).”

• cites [29] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med sourceSupported

May combine two claims.

SGLT2 inhibitors slow CKD progression and reduce heart failure risk independent of their effects on glucose in people with type 2 diabetes and eGFR ≥20 mL/min/1.73m2.

“SGLT2 inhibitors are recommended for people with eGFR ≥20 mL/min/1.73m 2 and type 2 diabetes, as they slow CKD progression and reduce heart failure risk independent of their effects on glucose (117).”

• cites [117] McGuire, 2021, Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis, JAMA Cardiol sourcePartly supported

  The Results report reduced kidney-disease progression, and the Discussion reports reduced heart-failure hospitalization risk and recommendations independent of glucose considerations. But the Discussion supports a recommendation for eGFR ≥30 mL/min/1.73 m², not the claimed ≥20 threshold; page numbers are not available in our copy. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

In EMPA-KIDNEY, empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82]; P < 0.001).

“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”

• cites [128] Herrington, 2023, Empagliflozin in patients with chronic kidney disease, N Engl J Med sourcePartly supported

  The Results (Primary and Secondary Outcomes) report HR 0.72 (95% CI 0.64–0.82; P<0.001) for the composite of kidney disease progression or cardiovascular death, not for both outcomes separately. Kidney disease progression had HR 0.71, but cardiovascular death alone had HR 0.84 (95% CI 0.60–1.19), so the paper does not establish a lower risk of cardiovascular death on its own. (LLM, conf=0.91)

  Experimental — accuracy not yet measured

May combine two claims.

GLP-1 RAs reduce risks of cardiovascular disease events and slow progression of CKD.

“GLP-1 RAs are suggested for cardiovascular risk reduction if such risk is a predominant problem, as they reduce risks of CVD events and slow progression of CKD (109,118-122).”

• cites [109] Perkovic, 2024, Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes, N Engl J Med sourceNot checked — no full text of the source
• cites [118] Zelniker, 2019, Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus, Circulation sourceNot checked — no full text of the source
• cites [119] Mann, 2020, Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials, Lancet Diabetes Endocrinol sourceNot checked — no full text of the source
• cites [120] Mann, 2021, Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists, Kidney Int sourceNot checked — no full text of the source
• cites [121] Neuen, 2024, Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis, Circulation sourceNot checked — no full text of the source
• cites [122] Kelly, 2022, Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis, Pharmacotherapy sourcePartly supported

  The Conclusion says select GLP-1 receptor agonists have reduced cardiovascular event rates, but this meta-analysis found no significant reduction in the composite cardiovascular endpoint for patients with type 2 diabetes and CKD; it does not establish a class-wide effect. The Introduction mentions renoprotection and recommends agents with demonstrated renal benefit, but the paper does not establish that GLP-1 receptor agonists slow CKD progression. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Recent data support that SGLT2 inhibitors reduce oxidative stress in the kidney by >50% and blunt increases in angiotensinogen as well as reduce NLRP3 inflammasome activity.

“Moreover, recent data support the notion that SGLT2 inhibitors reduce oxidative stress in the kidney by >50% and blunt increases in angiotensinogen as well as reduce NLRP3 inflammasome activity (100,102,103).”

• cites [100] Girardi, 2024, Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions, Am J Physiol Cell Physiol sourceNot checked — no full text of the source
• cites [102] Woods, 2019, Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus, Am J Nephrol sourcePartly supported

  The Results section on renal oxidative stress reports that canagliflozin lowered urinary 8-isoprostane from 8.9 to 2.8 ng/day at week 6 in diabetic mice, a reduction greater than 50%. The Discussion concludes that canagliflozin suppresses intrarenal oxidative stress and angiotensinogen upregulation. Our copy does not report reduced NLRP3 inflammasome activity, and these findings concern canagliflozin in a mouse model rather than SGLT2 inhibitors generally. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [103] Heerspink, 2019, Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease, Diabetologia sourcePartly supported

  The Discussion reports that canagliflozin lowered inflammatory biomarkers and suggests anti-inflammatory effects, which broadly supports the inflammation aspect of the sentence. It does not report a >50% reduction in kidney oxidative stress, blunted increases in angiotensinogen, or reduced NLRP3 inflammasome activity. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Most participants with CKD in these trials also had diagnosed ASCVD at baseline, although ∼28% of CANVAS participants with CKD did not have diagnosed ASCVD.

“Most participants with CKD in these trials also had diagnosed atherosclerotic cardiovascular disease (ASCVD) at baseline, although ∼28% of CANVAS participants with CKD did not have diagnosed ASCVD (32).”

• cites [32] Neuen, 2018, Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function, Circulation sourceSupported

May combine two claims.

In FIGARO-DKD, there was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.

“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”

• cites [144] Pitt, 2021, Cardiovascular events with finerenone in kidney disease and type 2 diabetes, N Engl J Med sourcePartly supported

  The Safety Outcomes and Vital Signs section reports hyperkalemia in 10.8% of the finerenone group versus 5.3% of the placebo group, and permanent discontinuation of the trial regimen in 1.2% of finerenone patients. The Results section gives 3,686 patients in the finerenone analysis group. The paper says they stopped the regimen, not that they left the study. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Subgroup analyses from DAPA-CKD and analyses from the EMPEROR heart failure trials suggest that SGLT2 inhibitors are safe and effective at eGFR levels of >20 mL/min/1.73m2.

“Subgroup analyses from DAPA-CKD (133) and analyses from the EMPEROR heart failure trials suggest that SGLT2 inhibitors are safe and effective at eGFR levels of >20 mL/min/ 1.73 m 2 .”

• cites [133] Chertow, 2021, Effects of dapagliflozin in stage 4 chronic kidney disease, J Am Soc Nephrol sourcePartly supported

  The paper’s stage 4 DAPA-CKD analysis reports benefits without increased adverse-event risks, supporting safety and effectiveness in that subgroup. But the Abstract states that DAPA-CKD enrolled participants with baseline eGFR of 25–75 mL/min/1.73 m²; its subgroup analysis does not establish those findings across the full range above 20. The Discussion attributes enrollment down to 20 to EMPEROR-Reduced, not DAPA-CKD. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

FIDELIO-DKD demonstrated a significant reduction in CKD progression and cardiovascular events in people with diabetes and advanced CKD.

“the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial, which examined the kidney effects of finerenone, an nsMRA, demonstrated a significant reduction in CKD progression and cardiovascular events in people with diabetes and advanced CKD (33,143).”

• cites [33] Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med sourceSupported
• cites [143] Filippatos, 2021, Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes, Circulation sourceSupported

May combine two claims.

In the CONFIDENCE trial, simultaneous initiation of finerenone and empagliflozin led to a reduction in UACR at 180 days of 52% with combination therapy, which was 32% greater than that with empagliflozin alone and 29% greater than that with finerenone alone.

“Simultaneous initiation of finerenone and empagliflozin led to a reduction in the UACR at 180 days of 52% with combination therapy, which was 32% greater than that with empagliflozin alone and 29% greater than that with finerenone alone (148).”

• cites [148] Agarwal, 2025, Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes, N Engl J Med sourcePartly supported

  The Abstract reports that at day 180, the UACR reduction with initial combination therapy was 32% greater than with empagliflozin alone and 29% greater than with finerenone alone. The passages in our copy do not report the claimed 52% reduction with combination therapy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Most GLP-1 RAs may be used at low eGFR for cardiovascular protection but may require dose adjustment.

“Of note, most GLP-1 RAs may also be used at low eGFR for cardiovascular protection but may require dose adjustment (125).”

• cites [125] Bakris, 2019, Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors, Am J Kidney Dis sourcePartly supported

  The paper's main text (page not provided) reports that GLP-1 receptor agonists reduced cardiovascular event rates in outcome trials. It does not say that most can be used at low eGFR or that dose adjustment may be required; its discussion of low eGFR concerns SGLT2 inhibitors. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

This observational study had methodological issues, including the likely inclusion of individuals with AKI.

“However, this study had methodological issues, including the likely inclusion of individuals with AKI (158).”

• cites [158] Lai, 2024, Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists, Cardiovasc Diabetol sourceSupported

Classified as probably not a substantial claim. May combine two claims.

Diuretics are not recommended for blood pressure management in pregnancy but may be used during late-stage pregnancy if needed for volume management.

“Diuretics are not recommended for blood pressure management in pregnancy but may be used during latestage pregnancy if needed for volume management (151).”

• cites [151] Garovic, 2022, Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association, Hypertension sourcePartly supported

  The 'Antihypertensive medications' section (page unavailable) says diuretics are not used often in pregnant women, but it does not say they are categorically not recommended for blood-pressure management. It describes possible use in women with salt-sensitive chronic hypertension or chronic kidney disease and reduced GFR, not specifically during late-stage pregnancy for volume management. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

The American College of Obstetricians and Gynecologists recommends that, postpartum, individuals with gestational hypertension, preeclampsia, and superimposed preeclampsia have their blood pressures observed for 72 h in the hospital and 7-10 days postpartum.

“The American College of Obstetricians and Gynecologists also recommends that, postpartum, individuals with gestational hypertension, preeclampsia, and superimposed preeclampsia have their blood pressures observed for 72 h in the hospital and 7-10 days postpartum.”

• cites [152] Irgens, 2001, Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study, BMJ sourceCould not verify

  The Materials and methods section (page not provided) defines pre-eclampsia cases, and the Discussion addresses cardiovascular risk years later. Neither addresses an American College of Obstetricians and Gynecologists recommendation for postpartum blood-pressure observation. Searches for the organization and the 72-hour and 7–10-day intervals found no supporting passage. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Long-term follow-up is recommended for individuals with gestational hypertension, preeclampsia, and superimposed preeclampsia, as they have increased lifetime cardiovascular risk.

“Long-term follow-up is recommended for these individuals, as they have increased lifetime cardiovascular risk (152).”

• cites [152] Irgens, 2001, Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study, BMJ sourcePartly supported

  The Discussion reports increased later cardiovascular risk for women with pre-eclampsia who delivered preterm, but says those who delivered at term had no increased cardiovascular mortality. The copy does not recommend long-term clinical follow-up or establish the stated risk for gestational hypertension or superimposed pre-eclampsia. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, labetalol, and long-acting nifedipine, while hydralazine may be considered in the acute management of hypertension in pregnancy or severe preeclampsia.

“Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, labetalol, and longacting nifedipine, while hydralazine may be considered in the acute management of hypertension in pregnancy or severe preeclampsia (151).”

• cites [151] Garovic, 2022, Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association, Hypertension sourcePartly supported

  The Antihypertensive medications section identifies labetalol and methyldopa as accepted first-line drugs and reports comparable safety and efficacy for hydralazine, labetalol, and nifedipine in acute severe hypertension. It also notes that not all societies recommend nifedipine as initial therapy and that fetal-safety data are limited, so the unqualified description of all three as known to be safe in pregnancy overstates the source. The copy provides no page numbers for these passages. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

In an observational study, use of GLP-1-based therapy at the onset of dialysis was associated with a decreased risk of major cardiovascular events (adjusted HR 0.65, P < 0.001) and all-cause mortality (adjusted HR 0.63, P < 0.001) during a median follow-up of 1.4 years.

“In an observational study, use of GLP-1-based therapy at the onset of dialysis was associated with a decreased risk of major cardiovascular events (adjusted HR 0.65, P < 0.001) and all-cause mortality (adjusted HR 0.63, P < 0.001) during a median follow-up of 1.4 years.”

• cites [158] Lai, 2024, Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists, Cardiovasc Diabetol sourceSupported

Classified as probably not a substantial claim.

Based on the current classification system, both eGFR and albuminuria must be quantified to guide treatment decisions.

“Thus, based on the current classification system, both eGFR and albuminuria must be quantified to guide treatment decisions.”

Classified as probably not a substantial claim.

These interventions may be most important for individuals with reduced eGFR, for whom urinary excretion of sodium and potassium may be impaired.

“These interventions may be most important for individuals with reduced eGFR, for whom urinary excretion of sodium and potassium may be impaired.”

Classified as probably not a substantial claim. May combine two claims.

For individuals on dialysis, higher levels of protein intake should be considered since protein-energy wasting is a major problem for some individuals on dialysis.

“For individuals on dialysis, higher levels of protein intake should be considered since protein-energy wasting is a major problem for some individuals on dialysis (53).”

• cites [53] Murray, 2018, Is dietary protein intake predictive of 1-year mortality in dialysis patients?, Am J Med Sci sourceNot checked — no full text of the source

May combine two claims.

In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria, slowed CKD progression, and reduced cardiovascular events but has not reduced progression to kidney failure.

“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria (≥300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to kidney failure (75,78).”

• cites [75] Heart Outcomes Prevention Evaluation Study Investigators, 2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet sourceNot checked — no full text of the source
• cites [78] Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med sourceNot checked — no full text of the source

May combine two claims.

In the absence of kidney disease, ACE inhibitors or ARBs are useful to manage blood pressure but have not proven superior to alternative classes of antihypertensive therapy, including thiazide-like diuretics and dihydropyridine calcium channel blockers.

“In the absence of kidney disease, ACE inhibitors or ARBs are useful to manage blood pressure but have not proven superior to alternative classes of antihypertensive therapy, including thiazide-like diuretics and dihydropyridine calcium channel blockers (93).”

• cites [93] Ichikawa, 2025, Efficacy of renin-angiotensin system inhibitors, calcium channel blockers, and diuretics in hypertensive patients with diabetes: subgroup analysis based on albuminuria in a systematic review and meta-analysis, Hypertens Res sourceNot checked — no full text of the source

May combine two claims.

People with CKD are at increased risk of CKD progression (particularly those with albuminuria) and CVD.

“People with CKD are at increased risk of CKD progression (particularly those with albuminuria) and CVD; therefore, lower blood pressure goals may be suitable in some cases, especially in individuals with severely elevated albuminuria (≥300 mg/g creatinine) (83).”

• cites [83] Jones, 2025, 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Hypertension sourceNot checked — no full text of the source

May combine two claims.

SGLT2 inhibitors have demonstrated reduced risk of heart failure hospitalizations and some also demonstrated cardiovascular risk reduction.

“With respect to cardiovascular outcomes, SGLT2 inhibitors have demonstrated reduced risk of heart failure hospitalizations and some also demonstrated cardiovascular risk reduction.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

GLP-1 RAs have clearly demonstrated cardiovascular benefits.

“GLP-1 RAs have clearly demonstrated cardiovascular benefits.”

May combine two claims.

These analyses were limited by evaluation of study populations not selected primarily for CKD and examination of kidney effects as secondary outcomes.

“These analyses were limited by evaluation of study populations not selected primarily for CKD and examination of kidney effects as secondary outcomes.”

May combine two claims.

Lixisenatide and exenatide require the kidneys for elimination, result in higher exposure, and have limited data in individuals with eGFR <30 mL/min/1.73m2 or creatinine clearance <30 mL/min, respectively.

“Lixisenatide and exenatide, which require the kidneys for elimination, result in higher exposure to the medication and have limited data in individuals with eGFR <30 mL/min/1.73m 2 or creatinine clearance <30 mL/min, respectively (137-139).”

• cites [137] AstraZeneca . Bydureon prescribing information. Accessed 18 September 2025. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdfNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [138] Sanofi . Lixisenatide prescribing information. Accessed 18 September 2025. Available from https://products.sanofi.us/soliqua100-33/soliqua100-33.pdfNot matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [139] Scheen, 2015, Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes, Clin Pharmacokinet sourceNot checked — no full text of the source

May combine two claims.

There are two different classes of MRAs, steroidal and nonsteroidal, with one group not extrapolatable to the other.

“There are two different classes of MRAs, steroidal and nonsteroidal, with one group not extrapolatable to the other (142).”

• cites [142] Huart, 2025, Non-steroidal mineralocorticoid receptor antagonists: a paradigm shift in the management of diabetic nephropathy, Kidney Blood Press Res sourceNot checked — no full text of the source

May combine two claims.

The FLOW study supports a beneficial effect of semaglutide in slowing decline in kidney function as well as being cardioprotective in people with CKD and type 2 diabetes.

“Thus, this kidney outcome study supports a beneficial effect of semaglutide in slowing decline in kidney function as well as being cardioprotective in people with CKD and type 2 diabetes.”

• cites [109] Perkovic, 2024, Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes, N Engl J Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based).

All of the recent kidney and cardiovascular outcomes studies for individuals with diabetes and CKD were completed in the setting of maximally tolerated RAS blockade.

“All of the recent kidney and cardiovascular outcomes studies for individuals with diabetes and CKD were completed in the setting of maximally tolerated RAS blockade.”

May combine two claims.

In FLOW, participants who took semaglutide had lower A1C, lower blood pressure, and more weight loss.

“Of note, the participants who took semaglutide had lower A1C, lower blood pressure, and more weight loss-all of which are beneficial for slowing decline in kidney function and reducing cardiovascular adverse events.”

• cites [109] Perkovic, 2024, Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes, N Engl J Med sourceNot checked — no full text of the source

May combine two claims.

In SURMOUNT-2, only 5% of participants had eGFR <60 mL/min/1.73m2 and 31% had albuminuria at baseline.

“However, only 5% of the participants had eGFR <60 mL/min/1.73m 2 , and 31% had albuminuria at baseline.”

May combine two claims.

In a national cohort study of 151,649 individuals with type 2 diabetes initiating dialysis between 2013 and 2021, GLP-1-based therapy was associated with a 23% lower mortality and 66% higher chance of transplant waitlisting.

“In a national cohort study of 151,649 individuals with type 2 diabetes initiating dialysis between 2013 and 2021, GLP-1-based therapy was associated with a 23% lower mortality and 66% higher chance of transplant waitlisting (157).”

• cites [157] Orandi, 2025, GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis, Clin J Am Soc Nephrol sourceNot checked — no full text of the source

May combine two claims.

Complications of CKD generally become prevalent when eGFR falls below 60 mL/min/1.73m2 (stage G3 CKD or greater) and become more common and severe as CKD progresses.

“Complications of chronic kidney disease (CKD) generally become prevalent when estimated glomerular filtration rate falls below 60 mL/min/1.73m 2 (stage G3 CKD or greater) and become more common and severe as CKD progresses.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Laboratory evaluations are generally indicated every 6-12 months for stage G3 CKD, every 3-5 months for stage G4 CKD, and every 1-3 months for stage G5 CKD, or as indicated to evaluate symptoms or changes in therapy.

“laboratory evaluations are generally indicated every 6-12 months for stage G3 CKD, every 3-5 months for stage G4 CKD, and every 1-3 months for stage G5 CKD, or as indicated to evaluate symptoms or changes in therapy.”

Classified as probably not a substantial claim.

During pregnancy, treatment with ACE inhibitors, ARBs, direct renin inhibitors, MRAs, SGLT2 inhibitors, and neprilysin inhibitors is contraindicated, as they may cause fetal damage.

“During pregnancy, treatment with ACE inhibitors, ARBs, direct renin inhibitors, MRAs, SGLT2 inhibitors, and neprilysin inhibitors is contraindicated, as they may cause fetal damage.”

May combine two claims.

Consultation with a nephrologist when stage G4 CKD develops (eGFR <30 mL/min/1.73m2) has been found to reduce cost, improve quality of care, and delay the need for dialysis.

“Consultation with a nephrologist when stage G4 CKD develops (eGFR <30 mL/min/1.73m 2 ) has been found to reduce cost, improve quality of care, and delay the need for dialysis (159).”

• cites [159] Smart, 2014, Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease, Cochrane Database Syst Rev sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based).

SGLT2 inhibitors have non-kidney effects in multiple organs, including the cardiovascular system.

“SGLT2 inhibitors have non-kidney effects in multiple organs, including the cardiovascular system.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Figure 11.1 parameters are general parameters based only on expert opinion and underlying comorbid conditions.

“These are general parameters based only on expert opinion and underlying comorbid conditions, and disease state must be taken into account, as should the likelihood of impacting a change in management for any individual.”